The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

bone edema/osteitis using low-field MRI analysis of 25 anatomical locations in the wrist and hand and scoring the volume of the original articular bone in 0.5 increments from 0-3, with each increment in the scale representing 33% of the volume of the peripheral 1 cm of original (eroded + residual) articular bone.

Time Frame

MRIs at Baseline and Week 48

Outcome Measure Data Outcome Measure Data

Analysis Population Description

Analysis Population Description

osteitis on the MRIs from 27 patients at baseline and week 48

Arm/Group Title

Abatacept

Arm/Group Description:

open label use of abatacept for 12 ...

Arm/Group Description:

open label use of abatacept for 12 months

abatacept: Abatacept administered SC weekly at 125 mg dose

Overall Number of Participants Analyzed

27

Measure Type: Number

Unit of Measure: participants

27

2.Secondary Outcome

Title

Patients With an Improvement in DAS Score Were Considered Responders at Week 48

Description

Patient with a positive change in DAS score were considered responders...

Description

Patient with a positive change in DAS score were considered responders . The DAS score is calculated using the number of tender and swollen joints based upon a 28 joint count, the ESR in mm/hr., and the physician global score

Time Frame

The DAS 28 score will be performed at baseline and 48

Outcome Measure Data Outcome Measure Data

Analysis Population Description

Analysis Population Description

There were 34 enrolled patients with 7 patients who early termed so analysis was performed on 27 patients

Arm/Group Title

Abatacept

Arm/Group Description:

open label use of abatacept for 12 ...

Arm/Group Description:

open label use of abatacept for 12 months

abatacept: Abatacept administered SC weekly at 125 mg dose

Overall Number of Participants Analyzed

27

Measure Type: Number

Unit of Measure: participants

25

3.Secondary Outcome

Title

To Measure the Change From Baseline in Patient DAS 28 Scores at Baseline and Weeks 12, 24

Description

DAS 28> 5.1=high disease activity DAS28 <3.2=low disease activit...

Description

DAS 28> 5.1=high disease activity DAS28 <3.2=low disease activity DAS28 <2.6=remission Criteria used in formula are number of tender joints based upon 28 joints, number of swollen joints based on 28 joints, ESR in mm/hr and patient global health core based on 0-10 mm

Time Frame

Patient DAS 28 scores will be measured at baseline and weeks 12, 24, 48 and disease activity will be recorded at Week 48

Outcome Measure Data Outcome Measure Data

Analysis Population Description

Analysis Population Description

the number of participants who reached remission, low disease activity, moderate disease activity and high disease activity will be determined as based upon the DAS scale

Arm/Group Title

Abatacept

Arm/Group Description:

open label use of abatacept for 12 ...

Arm/Group Description:

open label use of abatacept for 12 months

abatacept: Abatacept administered SC weekly at 125 mg dose

Overall Number of Participants Analyzed

27

Measure Type: Number

Unit of Measure: participants

clinical remission at week 12

2

low disease activity at week 12

2

mod disease activity at week 12

12

high disease activity at week 12

11

clinical remission at week 24

1

low disease activity at week 24

2

moderate disease activity at week 24

14

high disease activity at week 24

8

clinical remission at week 48

4

low disease activity at week 48

6

moderate disease activity at week 48

8

high disease activity at week 48

7

4.Secondary Outcome

Title

the Clinical Outcomes Measurements (American College of Rheumatology Activity Scoring, Health Assessment The Number of Patients With a Clinical Response at Week 24 and 48

Description

Patient with a positive change in DAS score were considered responders...

Description

Patient with a positive change in DAS score were considered responders . The DAS score is calculated using the number of tender and swollen joints based upon a 28 joint count, the ESR in mm/hr., and the physician global score (1-10 cm). Total maximum score was at high disease activity at baseline.

Time Frame

week 24 and Week 48

Outcome Measure Data Outcome Measure Data

Analysis Population Description

Analysis Population Description

There were 34 enrolled patients with 7 patients who early termed so analysis was performed on 27 patients

Arm/Group Title

Abatacept

Arm/Group Description:

open label use of abatacept for 12 ...

Arm/Group Description:

open label use of abatacept for 12 months

abatacept: Abatacept administered SC weekly at 125 mg dose

Overall Number of Participants Analyzed

27

Measure Type: Number

Unit of Measure: participants

clinical response at 6 months

20

clinical response at 12 months

25

5.Secondary Outcome

Title

Number of Patients With Adverse Events

Description

site will report the number of patients with adverse envents from Day ...

Description

site will report the number of patients with adverse envents from Day 1 up to 52 weeks

Time Frame

all adverse events will be captured from Day 1 up to 52 weeks

Outcome Measure Data Outcome Measure Data

Analysis Population Description

Analysis Population Description

There were 34 enrolled patients with 7 patients who early termed so analysis was performed on 27 patients